Why do children fall ill
more severely than adults?
Polyoxidonium®: combined action
for ARVI and influenza treatment
The drug can:
Pharmaceutical form

Children aged 3 years and older
Schedule of administration of tablets 12 mg
for the treatment of acute respiratory infections

Children aged 6 years and older
Suppositories 6 mg
for the treatment of acute respiratory infections
Polyoxidonium® can take care of every child
Polyoxidonium® for the prevention of viral infections


Polyoxidonium® can have prolonged preventive action:
- helps boost immunity5,
- activates factors of early protection from viral infections5,
- reduces ARVI and influenza reoccurrence7.
The major part of the children can be excluded from the group of frequently and chronically ill children after the treatment8.
Dosing schedule of Polyoxidonium® tablets 12 mg for the prevention of acute respiratory infections
- Yarilin, A.A. (2010). Immunology, Moscow, GEOTAR-Media, 752, 520.
- Isaeva, E.I., et al. (2019). Study of antiviral activity of Polyoxidonium on an experimental in vitro model. Journal of Infectology, vol. 11, No.1, app. 1, 5–13.
- Karaulov, A.V., Gorelov, A.V. (2019). The use of azoximer bromide for treatment of inflammatory infections of respiratory system in children: a meta-analysis of controlled clinical studies. Journal of Infectology, vol. 11, No. 4, 31–41.
- Morozova, S.V. (2010). The use of Polyoxidonium® immunocorrecting drug in acute infectious inflammatory pathology of ENT-organs. Russian Medical Journal, vol. 18, No. 24.
- Patient information leaflet for Polyoxidonium®.
- Letter of the Russian Association of Allergologists and Clinical Immunologists.
- Kharit, S.M., Galustyan, A.N. (2017). Azoximer bromide is a safe and effective drug for treatment of acute upper respiratory tract infections in children: an overview of the results of double-blind, placebo-controlled, randomized clinical trials of phase II and III. Pediatrics (Appendix to Consilium Medicum), 2.
- Mustafaev, D.M., Yegorov, V.I. (2016). Immunomodulatory therapy in ENT practice. Medical Council, No. 18.